Use of mitomycin C in endo-DCR

Ghosh, Soumitra; Roychoudhury, Amitabha; Roychaudhuri, B. K.

doi:10.1007/bf03049597

Cited by 26 publications

(26 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, a majority (92.0%) of respondents never used or infrequently used topical antimetabolites. Multiple level‐1 evidence studies have demonstrated no benefit with mitomycin C in primary EnDCR . This was confirmed in a recent meta‐analysis .…”

Section: Discussionmentioning

confidence: 70%

Practice patterns in endoscopic dacryocystorhinostomy: survey of the American Rhinologic Society

Chen

Liang

2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 70%

Practice patterns in endoscopic dacryocystorhinostomy: survey of the American Rhinologic Society

Chen

Liang

2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

show abstract

“…One study was divided into two comparative groups as it included both primary and revision DCRs. Three studies were done in India [12], [13], [33], 3 in Turkey [11], [30], [32], and 1 each in Iran [15], Finland [34], Egpty [35], Thailand [14], and China [10]. The mean age of patients in most of studies ranged from 32 to 70 years and the percentage of female patients ranged from 42% to 90%.…”

Section: Resultsmentioning

confidence: 99%

“…The results are as follows: Subgroup 1 (primary EN-DCR, eight studies [10], [12]–[15], [31]–[33], recruiting 420 eyes) [RR = 1.09, 95% CI (1.00, 1.18), P = 0.045; Figure 4]; Subgroup 2 (revision EN-DCR, four studies [11], [31], [34], [35], recruiting 144 eyes) [RR = 1.21, 95% CI (1.02, 1.45), P = 0.029; Figure 4]; Subgroup 3 (EN-DCR without silicone intubation, six studies [10], [12], [13], [32]–[34], recruiting 285 eyes) [RR = 1.15, 95% CI (1.03, 1.27), P = 0.010; Figure 5]; Subgroup 4 (EN-DCR with silicone intubation, five studies [11], [14], [15], [31], [35], recruiting 289 eyes) [RR = 1.09, 95% CI (0.98, 1.21), P = 0.122; Figure 5]. All the results indicated that MMC group had a higher success rate except the subgroup of EN-DCR with silicone intubation.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis

Cheng

Feng

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundA number of published comparative studies have been conducted to evaluate the efficacy and safety of intraoperative mitomycin C (MMC) in endoscopic dacryocystorhinostomy (EN-DCR). However, results have not always been consistent. Therefore, we carried out a meta-analysis to compare the clinical results of EN-DCR with and without MMC.Methods and FindingsA comprehensive literature search of Cochrane Library, PubMed and EMBASE to identify relevant trials comparing EN-DCR with and without MMC. Eleven studies including 574 eyes were included in this meta-analysis. The success was defined as patency of the nasolacrimal canal and symptomatic improvement. There was significantly higher success rate in the MMC group in comparison with control group [RR = 1.12, 95% CI (1.04, 1.20), P = 0.004]. A sensitivity analysis after the non-randomized controlled trials were excluded from the meta-analysis demonstrated no differences compared with the overall results. Subgroup analyses showed that MMC group had a significantly higher success rate than control group in primary and revision EN-DCR, and EN-DCR without silicone intubation, but no difference in the subgroup of with silicone intubation. The size of the osteotomy site was bigger in the MMC group compared to the control group at 3 months [WMD = 7.65, 95% CI (0.33, 14.98), P = 0.041] and 6 months [WMD = 9.28, 95% CI (2.45, 16.11), P = 0.008] after surgery. However, there was statistically significant difference in the osteotomy surface area between the two groups at 12 months after surgery [WMD = 11.63, 95% CI (−1.04, 24.29), P = 0.072].ConclusionIntraoperative MMC application seems to be a safe adjuvant that could reduce the closure rate of the osteotomy and enhance the success rate after both primary and revision EN-DCR.Trial RegistrationClinicalTrials.gov NCT01772277

show abstract

“…In order to prevent excessive scar formation Mitomycin C has been used as a surgical adjuvant in glaucoma filtration surgery and pterygium excision. More recently its use has been described in primary lacrimal drainage surgery [5,6]. The beneficial effect of Mitomycin C (MMC) as a surgical adjuvant is thought to be related to its potent inhibition of fibroblast proliferation [5,6].…”

Section: Introductionmentioning

confidence: 99%

Prospective Randomized Comparison of Mitomycin C Application in Endoscopic and External Dacryocystorhinostomy

Mudhol

Zingade

Mudhol

et al. 2011

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

The aim of the study is to compare the subjective (relief of symptoms) and objective (endoscopic visualization of ostium patency at the time of syringing) outcomes at the end of two procedures-Endonasal DCR versus External DCR with Mitomycin C and to assess the role of Mitomycin C in maintaining patency of nasolacrimal drainage system. Prospective randomized comparative study was performed. Thirty-five patients were enrolled in each endoscopic and external dacryocystorhinostomy groups with Mitomycin C (MMC) application. The 37 eyes underwent endonasal DCR (28 unilateral primary eyes + 1 bilateral primary eyes + 5 unilateral revision eyes + 1 bilateral revision eye) while 35 eyes underwent external DCR (34 unilateral primary eyes + 1 unilateral revision eye). Mitomycin C 0.2 mg/ml was applied intra-operatively for 5 min to the ostium site at the end of endonasal or external DCR procedure. Objective assessment by syringing at the end of 1 year in the endonasal group showed 35 eyes (94%) were patent, 1 (3%) was partially blocked and 1(3%) was completely blocked; while in external group all 35 eyes (100%) were patent. Endoscopic visualization of the ostium at the time of syringing showed only one eye (3%) in the endonasal group was blocked while all the other eyes in both groups were patent. Both groups had a mean follow-up of 6-36 months. No complications were associated with use of Mitomycin C. In conclusion, intra-operative use of Mitomycin C in both endoscopic DCR and external DCR is safe and effective in increasing the success rate.

show abstract

Use of mitomycin C in endo-DCR

Abstract: Intraoperative Mitomycin C application does not alter the long-term results in endoscopic DCR. A properly and adequately performed surgery is more vital for successful result.

Cited by 26 publications

References 10 publications

Practice patterns in endoscopic dacryocystorhinostomy: survey of the American Rhinologic Society

Practice patterns in endoscopic dacryocystorhinostomy: survey of the American Rhinologic Society

Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis

Prospective Randomized Comparison of Mitomycin C Application in Endoscopic and External Dacryocystorhinostomy

Contact Info

Product

Resources

About